Cargando…

Immune checkpoint inhibitor-related pancreatitis: What is known and what is not

A 47-year-old man presented with a 1 week history of progressive fatigue and decreased appetite. He had stage IV oral squamous cell carcinoma and was treated with sintilimab, a programmed cell death protein 1 inhibitor, 22 months earlier. Laboratory work-up revealed significant elevation of bilirubi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Chunyan, Tang, Wen, Yang, Xu, Li, Hongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238808/ https://www.ncbi.nlm.nih.gov/pubmed/37273919 http://dx.doi.org/10.1515/med-2023-0713

Ejemplares similares

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Fatal Immune Checkpoint Inhibitor-related Pancreatitis
por: Ueno, Masayuki, et al.
Publicado: (2021)

Treatment of Extracranial Carotid Artery Aneurysms: What is Known and What is Unknown?
por: de Borst, G.J., et al.
Publicado: (2017)

Antipsychotics cardiotoxicity: What's known and what's next
por: Li, Xiao-Qing, et al.
Publicado: (2021)

The Infectious Pancreatic Necrosis Virus (IPNV) and its Virulence Determinants: What is Known and What Should be Known
por: Dopazo, Carlos P.
Publicado: (2020)

Utilization Behavior: What Is Known and What Has to Be Known?
por: Iaccarino, Leonardo, et al.
Publicado: (2014)

What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
por: Yin, Jiaxin, et al.
Publicado: (2022)

Coronavirus Disease 2019 in Neonates – What Is Known and What Needs to Be Known
por: Nayak, Manas, et al.
Publicado: (2020)

Question what is “known”
por: Heller, H. Craig
Publicado: (2021)

Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
por: Valind, Anders, et al.
Publicado: (2021)

Immune-checkpoint inhibitors for glioblastoma: what have we learned?
por: Omuro, Antonio
Publicado: (2022)

What’s in your water? A well-known risk for arsenic toxicity
por: Jegen, Dominika A., et al.
Publicado: (2023)

Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
por: Townsend, Matthew J., et al.
Publicado: (2023)

Graham–Little–Piccardi Syndrome: A Lens Through beyond What is Known
por: Saha, Abhijit, et al.
Publicado: (2016)

Pediatric Hepatocellular Adenomas: What Is Known and What Is New?
por: Espinoza, Andres F., et al.
Publicado: (2023)

Pathogenesis of multimorbidity—what is known?
por: Wetterling, Tilman
Publicado: (2020)

Stroke and Etiopathogenesis: What Is Known?
por: Ciarambino, Tiziana, et al.
Publicado: (2022)

Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
por: Lee, Seon-Mi, et al.
Publicado: (2023)

Checkpoint inhibitors: What gastroenterologists need to know
por: Ahmed, Monjur
Publicado: (2018)

What is the role of checkpoint inhibitors in neuroendocrine neoplasms?
por: Al-Toubah, Taymeyah, et al.
Publicado: (2020)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

Tick Immune System: What Is Known, the Interconnections, the Gaps, and the Challenges
por: Fogaça, Andréa C., et al.
Publicado: (2021)

Long COVID: what is known and what gaps need to be addressed
por: Krishna, Benjamin, et al.
Publicado: (2023)

Ion Channels in Inflammatory Processes: What Is Known and What Is Next?
por: Retamal, Mauricio A., et al.
Publicado: (2016)

Hyperglycemia and COVID-19: What was known and what is really new?
por: Ceriello, Antonio
Publicado: (2020)

Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New
por: Barp, Andrea, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2017)

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?
por: Thuny, Franck, et al.
Publicado: (2022)

Pathological Mechanisms in Diabetes of the Exocrine Pancreas: What’s Known and What’s to Know
por: Wei, Qiong, et al.
Publicado: (2020)

Intravesical bacillus Calmette-Guerin for bladder cancer: What is known? What is not? What is next?
por: Madbouly, Khaled
Publicado: (2013)

Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
por: Koda, Ryo, et al.
Publicado: (2018)

Augmented Renal Clearance: What Have We Known and What Will We Do?
por: Luo, Yifan, et al.
Publicado: (2021)

Laryngopharyngeal reflux concept: what is known and what should we focus on?()
por: Sirin, Seher, et al.
Publicado: (2019)

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
por: Cazzaniga, Marina Elena, et al.
Publicado: (2019)

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
por: Gravara, Luigi Della, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Hemorrhagic Gastritis
por: Mathialagan, Karthik, et al.
Publicado: (2023)

Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis
por: Tanabe, Junya, et al.
Publicado: (2020)

Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report
por: Fletcher, James, et al.
Publicado: (2022)

Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy
por: Zurko, Joanna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kk7p6eo90l31q9fr93lk1g7aeh